Opportunity ID: 283824

General Information

Document Type: Grants Notice
Funding Opportunity Number: W81XWH-16-GWIRP-CPA
Funding Opportunity Title: DoD Gulf War Illness Clinical Partnership Award
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Grant
Category of Funding Activity: Science and Technology and other Research and Development
Category Explanation:
Expected Number of Awards: 2
Assistance Listings: 12.420 — Military Medical Research and Development
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: May 13, 2016
Last Updated Date:
Original Closing Date for Applications: Oct 20, 2016
Current Closing Date for Applications: Oct 20, 2016
Archive Date: Nov 19, 2016
Estimated Total Program Funding: $2,400,000
Award Ceiling: $0
Award Floor: $0

Eligibility

Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Additional Information on Eligibility:

Additional Information

Agency Name: Dept. of the Army — USAMRAA
Description: The GWIRP Clinical Partnership Award mechanism is being offered for the first time in FY16.
The Clinical Partnership Award supports research into the diagnosis and treatment of GWI that will accelerate the movement of promising ideas in GWI research into clinical applications to benefit Veterans with GWI in a manner that would be less readily achievable through independent efforts. The intent of this award is to inform and advance clinical practice, not just from testing/evaluating treatments in a translational model, but also by individualizing treatment
plans, experimenting with potential treatments, or informing biomarker or pathophysiology research from a clinical case series and/or other research-informing clinical modalities. The award is designed to encourage multi-institutional, multidisciplinary research partnerships among two or three investigators, referred to as the Initiating Principal Investigator (PI) and the Partnering PI(s), each of whom will receive a separate award. There must be at least one laboratory scientist and at least one clinician participating in the partnership. A clinician is defined as an individual who is credentialed (possesses the necessary degrees, licenses, and other certifications) as a care provider in any relevant capacity at the institution of record. Applicants must have in place, or have well-justified prospects of, a suitable and sufficient GWI patient clinical care population. In addition, at least one partner must have significant experience in GWI research. Biographical sketches should include appropriate documentation of credentials.
Observations that drive a research hypothesis may be derived from a laboratory discovery, population-based studies, or a clinician’s firsthand knowledge from providing care to patients. While the ultimate goal of translational research is to move an observation forward into clinical application, members of the partnership should view translational research as a two-way continuum between bench and bedside. The research plan should involve a reciprocal flow of ideas and information within the partnership. The Initiating and Partnering PI(s) have different submission requirements; however, all partners must provide substantial intellectual input into the design of the research project and both PIs should contribute significantly to the development of the Project Narrative, Statement of Work (SOW), and other required components. A proposed project in which a clinical partner merely supplies tissue samples or access to patients does not meet the intent of this mechanism. Developmental pathways for translational research that may be useful for designing translational research studies for support under this mechanism may be found within the following resource: Hawk ET, Matrisian LM, Nelson WG, et al. 2008. The Translational Research Working Group Developmental Pathways: Introduction and Overview, Clin Cancer Res 14:5664-71. These pathways, while created for cancer research initiatives, have broad applicability to other areas of research, are comprehensive, and span the entire translational research continuum from discovery of a target to clinical trials.
The Clinical Partnership Award is not intended to support clinical trials, but may support correlative studies that are associated with an existing clinical trial or projects that optimize the design of future clinical trials. Limited exploratory clinical testing to establish feasibility of a potential approach or to aid in device or intervention refinement may be supported. Investigators seeking support for a clinical trial should utilize the FY16 GWIRP Treatment Evaluation Award mechanism; see http://cdmrp.army.mil/funding/gwirp.shtml. A clinical trial is defined as a prospective accrual of patients for a study where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction. For more information on distinguishing clinical trials from clinical research, a Human Subject Resource Document is provided at https://cdmrp.org/Program_Announcements_and_Forms/.
Link to Additional Information:
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

CDMRP Help Desk

301-682-5507
Email:help@eBRAP.org

Version History

Version Modification Description Updated Date

Folder 283824 Full Announcement-FY16 GWIRP CPA -> gwirp_fy16_cpa pa_gg.pdf

Packages

Agency Contact Information: CDMRP Help Desk
301-682-5507
Email: help@eBRAP.org
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
12.420 PKG00223506 May 13, 2016 Oct 20, 2016 View

Package 1

Mandatory forms

283824 RR_SF424_2_0-2.0.pdf

283824 RR_Budget_1_3-1.3.pdf

283824 RR_KeyPersonExpanded_2_0-2.0.pdf

283824 PerformanceSite_2_0-2.0.pdf

Optional forms

283824 RR_SubawardBudget30_1_3-1.3.pdf

2025-07-09T13:47:30-05:00

Share This Post, Choose Your Platform!

About the Author: